Incyte (INCY) Liabilities and Shareholders Equity (2010 - 2026)
Incyte (INCY) reported Liabilities and Shareholders Equity of $7.3 billion for Q1 2026, up 27.65% on a YoY basis from $5.7 billion in Q1 2025, and up 5.48% quarter-over-quarter from $7.0 billion in Q4 2025.
Incyte (INCY) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Incyte has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $7.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 27.65% year-over-year to $7.3 billion; the trailing twelve-month figure through Mar 2026 stood at $26.4 billion (up 26.74% YoY), and the FY2025 full-year result was $7.0 billion, up 27.8% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $7.3 billion, up from $7.0 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $7.3 billion in Q1 2026, with the low at $4.7 billion in Q2 2024.
- Historically, Liabilities and Shareholders Equity has averaged $6.0 billion across 5 years, with a median of $5.8 billion in 2025.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 38.04% — and 2024, when it retreated 24.91%.
- Incyte's Liabilities and Shareholders Equity stood at $5.8 billion in 2022, then advanced by 16.11% to $6.8 billion in 2023, then declined by 19.73% to $5.4 billion in 2024, then gained by 27.8% to $7.0 billion in 2025, then rose by 5.48% to $7.3 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $7.3 billion (Q1 2026), $7.0 billion (Q4 2025), and $6.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 7.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.34 Bn |
| Dec 31, 2025 | 6.96 Bn |
| Sep 30, 2025 | 6.33 Bn |
| Jun 30, 2025 | 5.82 Bn |
| Mar 31, 2025 | 5.75 Bn |
| Dec 31, 2024 | 5.44 Bn |
| Sep 30, 2024 | 5.01 Bn |
| Jun 30, 2024 | 4.66 Bn |
| Mar 31, 2024 | 7.14 Bn |
| Dec 31, 2023 | 6.78 Bn |
| Sep 30, 2023 | 6.39 Bn |
| Jun 30, 2023 | 6.21 Bn |
| Mar 31, 2023 | 5.80 Bn |
| Dec 31, 2022 | 5.84 Bn |
| Sep 30, 2022 | 5.51 Bn |
| Jun 30, 2022 | 5.32 Bn |
| Mar 31, 2022 | 5.05 Bn |
| Dec 31, 2021 | 4.93 Bn |
| Sep 30, 2021 | 4.20 Bn |
| Jun 30, 2021 | 3.90 Bn |